mutation class

Small Mutation

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

315 sites for NCT04497844

ATM Loss, +61 more biomarkers

Prostate Adenocarcinoma

abiraterone, +2 more drugs

hormone therapy, +1 more type

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

106 sites for NCT03742895

ATM Loss, +62 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib

targeted therapy

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

259 sites for NCT03609216

ARID1A Loss, +122 more biomarkers

Bladder Urothelial Carcinoma

chemoradiotherapy, +6 more drugs

chemotherapy, +3 more types

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

6 sites for NCT03767075

ATM Loss, +94 more biomarkers

Malignant Solid Tumor

atezolizumab

immunotherapy

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

1 site for NCT04849364

AKT1 Amplification, +141 more biomarkers

Invasive Breast Carcinoma

atezolizumab, +3 more drugs

chemotherapy, +2 more types

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

1 site for NCT04826341

ATM Loss, +64 more biomarkers

Malignant Solid Tumor, +1 more condition

berzosertib, +1 more drug

chemotherapy, +1 more type